Diabetes
Refine Search
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Pharmaceutical
Christine Roy-Duval has left her role as international clinical investigation director at French pharma major Sanofi’s diabetes unit to join metabolic diseases specialist Valbiotis. 21 March 2018
Biotechnology
Real-world data presented by France’s Sanofi show that the firm’s once-daily long-acting basal analogue Toujeo (gla-300) is associated with statistically significant improvements in HbA1c in patients with type 1 diabetes. 20 March 2018
Pharmaceutical
Novo Nordisk has presented plenty of evidence to show the effectiveness of semaglutide in diabetes, but that might not be the only widespread chronic disease where it can help patients. 19 March 2018
Pharmaceutical
During 2017, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter -2 (SGLT-2) inhibitors marketed across the seven major markets (USA, 5EU [France, Italy, Germany, Spain, UK], and Japan: 7MM) brought in more than $8 billion in combined sales 12 March 2018
Pharmaceutical
London-based AstraZeneca has released a new analysis of data from its real-world evidence based CVD-REAL study evaluating the outcomes for type-2 diabetes patients undergoing treatment with SGLT-2 inhibitors. 12 March 2018
Pharmaceutical
Active deal-maker Ligand Pharmaceuticals has granted Roivant Sciences exclusive global rights to develop and commercialize LGD-6972, Ligand’s glucagon receptor antagonist (GRA), under development for the treatment of type 1 and 2 diabetes. 7 March 2018
Pharmaceutical
AstraZeneca today announced that the European Medicines Agency has accepted the Marketing Authorization Variation for Forxiga (dapagliflozin), a selective SGLT-2 inhibitor, for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D). 5 March 2018
Pharmaceutical
Type 2 diabetes patients whose blood sugar levels were not adequately controlled on SGLT-2 inhibitor therapy and metformin showed an improvement in average blood sugar concentration over two to three months (A1C) when Eli Lilly's Trulicity (dulaglutide) was added in a Phase IIIb study. 26 February 2018
Pharmaceutical
Following its monthly meeting in February, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended five medicines for approval, including two orphan medicines. 23 February 2018
Pharmaceutical
Ahead of next month’s annual general meeting, Danish diabetes giant Novo Nordisk has confirmed the recommendation that Helge Lund be named the new chairman of the board of directors. 23 February 2018
Biotechnology
Danish diabetes care giant Novo Nordisk has released positive top-line data from its Phase III PIONEER 1 trial of oral semaglutide for treatment of adults with type 2 diabetes. 22 February 2018
Pharmaceutical
French biopharma Poxel has seen a double-digit percentage increase in its share price on Monday after announcing news of a potentially lucrative deal with privately-held healthcare company Roivant Sciences. 12 February 2018
Pharmaceutical
Eli Lilly could face a bill in excess of $200 million if a French biotech’s charges against the US pharma company are upheld. 6 February 2018
Pharmaceutical
Novo Nordisk saw its share edge up this morning, after it announced that it is launching two new diabetes drugs in the USA. 5 February 2018
Pharmaceutical
While financial results released this morning by Novo Nordisk disappointed investors, there was better news from the Danish diabetes care giant with regard to new data investigating its semaglutide. 1 February 2018
Pharmaceutical
Danish diabetes giant Novo Nordisk took a 6% hit in the stock market on Thursday morning after announcing results from the fourth quarter of 2017 along with the full-year figures. 1 February 2018
Pharmaceutical
Fourth-quarter earnings per share (EPS) at Eli Lilly reflected a loss of $1.58 on a reported basis, and Wednesday’s trading hit the company’s hopes for healthy EPS in 2018. 31 January 2018
Pharmaceutical
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended seven medicines for approval, including one orphan medicine, at its January 2018 meeting. 26 January 2018
Pharmaceutical
Geropharm, one of Russia’s leading insulin producers, to invest 2 billion roubles ($35.3 million) in the establishment of insulin production in the city of Pushkin of the St Petersburg region of Russia. 25 January 2018
Biotechnology
New Zealand-based Living Cell Technologies has agreed to sell its 50% shareholding in joint venture company, Diatranz Otsuka Limited (DOL), to the other 50% shareholder, Japan’s Otsuka Pharmaceutical for $3 million, with settlement on January 31, 2018. 25 January 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze